KalVista director option grant — 30,000 shares at $12.05, 10/01/2025

Rhea-AI Filing Summary

KalVista Pharmaceuticals, Inc. director Brian JG Pereira was granted a stock option on 10/01/2025 to buy 30,000 shares of common stock at a conversion price of $12.05. The option was reported on Form 4 filed on 10/02/2025 and is exercisable in installments over a 12-month vesting schedule beginning 11/01/2025, with 1/12th of the total shares vesting initially and then monthly thereafter, subject to continued service. The option expires on 09/30/2035. Following the grant, Mr. Pereira directly beneficially owns 30,000 option shares.

Positive

• Director grant documented: Clear disclosure of a 30,000-share stock option at $12.05
• Standard vesting schedule: Time‑based 12‑month vesting beginning 11/01/2025, reducing execution uncertainty

Negative

• None.

Insights

Corporate Governance Analyst

Director received a time‑based stock option for 30,000 shares at $12.05.

The filing shows a standard compensation-related equity grant to a director: a 30,000-share stock option awarded on 10/01/2025 with a $12.05 exercise price and a 10-year term expiring on 09/30/2035. Vesting is fully time‑based over 12 months starting 11/01/2025, with monthly vesting thereafter, and ownership is reported as direct.

This is governance‑level disclosure of insider compensation rather than an operational or financing event. It is material to shareholders only insofar as it dilutes equity when exercised and signals board compensation practices; the Form 4 contains no additional transactions or unusual terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pereira Brian JG

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC.

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MA 01702

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$12.05	10/01/2025		A		30,000		(1)	09/30/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KalVista (KALV) disclose on this Form 4?

The Form 4 discloses a stock option grant to director Brian JG Pereira for 30,000 shares at an exercise price of $12.05, dated 10/01/2025.

When does the option vest and when does it expire?

Vesting begins on 11/01/2025 with 1/12th initially and monthly thereafter over 12 months; the option expires on 09/30/2035.

How many shares does the reporting person own after the transaction?

Following the grant, the reporting person directly beneficially owns 30,000 option shares.

Who filed the Form 4 and when was it signed?

The Form 4 was signed by Benjamin L. Palleiko, Attorney-in-Fact and filed on 10/02/2025.

What is the relationship of the reporting person to KalVista?

The reporting person, Brian JG Pereira, is disclosed as a Director of KalVista Pharmaceuticals.